Abstract
Conducting anticoagulant therapy for atrial fibrillation, combined with diabetes mellitus and/or chronic kidney disease, can create certain difficulties for practicing doctors due to a simultaneous increase in the risk of thromboembolic and hemorrhagic complications. The presence of diabetes mellitus and renal dysfunction can influence the results of antithrombotic therapy in patients with atrial fibrillation. The review provides information on the differences in efficacy and safety of individual oral anticoagulants in the prevention of thromboembolic complications of atrial fibrillation in patients with diabetes mellitus, impaired renal function.
Highlights
В последние годы среди населения развитых стран мира отмечается прогрессивное увеличение распространенности фибрилляции предсердий (ФП) и СД, поз воляющее констатировать настоящую неинфекционную пандемию [1, 2]
renal dysfunction can influence the results of antithrombotic therapy in patients
нарушение эндотелиальной функции во многом объясняют связь между СД и обусловленным
Summary
Conducting anticoagulant therapy for atrial fibrillation, combined with diabetes mellitus and / or chronic kidney disease, can create certain difficulties for practicing doctors due to a simultaneous increase in the risk of thromboembolic and hemorrhagic complica‐ tions. The presence of diabetes mellitus and renal dysfunction can influence the results of antithrombotic therapy in patients with atrial fibrillation. The review provides information on the differences in efficacy and safety of individual oral anticoagulants in the pre‐ vention of thromboembolic complications of atrial fibrillation in patients with diabetes mellitus, impaired renal function. СД является независимым ФР развития инсульта и других осложнений у пациентов с ФП [6]. Все это заставляет уделять особое внимание проведению профилактики тромбоэмболических осложнений при сочетании ФП и СД
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have